EVE Health Group Limited (AU:EVE)
ASX:EVE
Want to see AU:EVE full AI Analyst Report?
EVE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.04
Previous CloseN/A
Volume9.81K
Average Volume (3M)774.07K
Market Cap
AU$7.75M
Enterprise ValueAU$3.85M
Total Cash (Recent Filing)AU$929.66K
Total Debt (Recent Filing)AU$38.51K
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,326,600
10 Day Avg. Volume491,958
30 Day Avg. Volume774,070
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.22
Price to Sales (P/S)2.49
P/FCF Ratio-2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Capital StructureA very low debt-to-equity ratio (0.03) provides durable financial flexibility, lowering insolvency risk and preserving capacity to fund capex, working capital or strategic moves without heavy refinancing. This structural conservatism supports survival through cyclical pressure.
Improving Free Cash Flow MetricsReported improvement in free cash flow growth and a stable free cash flow to net income ratio (1.0) indicate strengthening cash generation relative to reported earnings. Durable FCF improvement helps fund operations or deleverage over time, reducing reliance on external capital.
Gross Profit Margin ImprovementNoted improvement in gross profit margins suggests better input cost management or product mix shifts. For a packaged foods business, sustained gross margin gains are a key structural lever to restore overall profitability once fixed-cost absorption and SG&A controls follow.
Bears Say
Declining Revenue TrendsMaterial and ongoing revenue declines undermine scale economics and indicate weakening market traction or distribution issues. Persistent top-line contraction reduces fixed-cost absorption and limits room for margin recovery, forcing reliance on restructuring or new product wins to reverse trend.
Persistent Unprofitability And Negative ROENegative net margins and a negative return on equity show the company is not generating returns for shareholders from its capital base. Over the medium term this hampers reinvestment, restricts strategic options, and risks capital erosion unless structural profitability fixes are executed.
Weak Operating Cash Conversion And Negative MarginsNegative operating cash flow combined with persistently negative EBIT/EBITDA margins indicates the business fails to convert sales into sustainable cash or operating profits. This structural cash conversion weakness pressures liquidity and forces dependence on external funding or asset sales.
EVE Health Group Limited News
EVE FAQ
What was EVE Health Group Limited’s price range in the past 12 months?
EVE Health Group Limited lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.
What is EVE Health Group Limited’s market cap?
EVE Health Group Limited’s market cap is AU$7.75M.
When is EVE Health Group Limited’s upcoming earnings report date?
EVE Health Group Limited’s upcoming earnings report date is Sep 02, 2026 which is in 72 days.
How were EVE Health Group Limited’s earnings last quarter?
EVE Health Group Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is EVE Health Group Limited overvalued?
According to Wall Street analysts EVE Health Group Limited’s price is currently Overvalued.
Does EVE Health Group Limited pay dividends?
EVE Health Group Limited does not currently pay dividends.
What is EVE Health Group Limited’s EPS estimate?
EVE Health Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EVE Health Group Limited have?
EVE Health Group Limited has 352,326,600 shares outstanding.
What happened to EVE Health Group Limited’s price movement after its last earnings report?
EVE Health Group Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of EVE Health Group Limited?
Currently, no hedge funds are holding shares in AU:EVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EVE Health Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:EVE Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$10.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-44.35%
Trailing 12-Months
Asset Growth
348.70%
Trailing 12-Months
Company Description
EVE Health Group Limited
Based in Subiaco, Australia, Eve Health Group Limited, originally incorporated in 2003 as EVE Investments Limited, is an international provider of health, wellness, and nutritional products. The company operates across Australia, New Zealand, the Asia Pacific region, and North America. Its activities include the production of organic tea tree oils, the distribution of botanical oils, and the supply of a wide array of other oils such as essential oils, hydrosols, extracts, carrier oils, and seed oils. Furthermore, Eve Health Group offers organic raw honey and raw honey probiotic concentrates, alongside contract manufacturing services. A key area of its focus is developing medical nutrition solutions for chronic and lifestyle ailments, exemplified by Gluco Smooth, a product designed to help manage type 2 diabetes by moderating post-meal blood sugar levels, as well as providing various dietary intervention programs.
Technical Analysis
―
Fiji Kava Limited
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―
Forbidden Foods Ltd
―
Options Prices
Currently, No data available
---